Top Pharmaceuticals Companies in Indonesia

The pharmaceuticals industry is a critical component of Indonesia's healthcare sector, providing essential medicines and contributing significantly to the country's GDP and employment figures. In this article, we will take a closer look at the pharmaceuticals industry in Indonesia, examining key statistics from 2022, factors contributing to its growth and success, industry trends, challenges, and future outlook.

read full article below
Filter bySearch by company name, registration number or domain name
CompanyHeadcountContactDescriptionDecision Maker
APOTEK MOSE0

ZYDUS GROUP10,582

PT DARYA - VARIA LABORATORIA1,149

ZAPRUDJE HEALTHCARE SERVICES LTD14

MCLINICA207

BINTANG TOEDJOE PHARMACEUTICALS21

VIFOR PHARMA2,161

YUNG SHIN PHARMACEUTICAL INDONESIA, PT29

PHARMADAYS UGM3

DANPAC PHARMA43

DANKOS FARMA PT442

LONZA15,346 +65 6521 4362

At Lonza, we enable #AHealthierWorld by supporting our healthcare customers on the path to commercialization. Our community of 16,000 talented employees work across a global network of more than 30 sites to deliver for our customers across the pharma, biotech and nutrition markets. By combining technological insight with world-class manufacturing, scientific expertise and process excellence, we help our customers to deliver new and innovative medicines that help treat a wide range of diseases.While we work in science, there’s no magic formula to how we do it. Our greatest scientific solution is talented people working together, devising commitment and ideas that help our customers to help people.In exchange, we let our people own their careers. Their ideas, big and small, genuinely improve the world. And that’s the kind of work we want to be part of.Our work makes #AMeaningfulDifference.

COMBIPHAR749 +62 800 1800088

Combiphar was founded in 1971 as a pharmaceutical company. Today, Combiphar is transforming into a modern consumer healthcare company that produces and markets more than 200 prescription and over-the-counter quality and affordable products, among others, OBH Combi cough syrup, Insto eye-care solution, JointFit gel-based relief for joints, CombiKid vitamin supplements, Privé green-tea based feminine hygiene wash, and Hezandra hepatoprotector supplement. Equipped with the latest production technology and the most up-to-date professional operation standards, Combiphar’s manufacturing plant, which is located in Padalarang, West Java, has most recently obtained the Therapeutic Goods Administration (TGA) Certification, allowing selected products to be exported to Australia. Additionally, Combiphar also has its own Research & Development facility, focusing on the quality optimization of prescription drugs to ensure that they meet the requirements of Bioavailability and Bioequivalence, as well as in the field of Nanotechnology. Combiphar has recently been ranked 2nd among local pharmaceutical companies recognized as “Indonesia’s Most Reputable Healthcare Brands 2015” (Onbee Research/SWA, May 2015) in terms of brand equity, customer loyalty, and customer experience.

MP BIOMEDICALS616 +65 6775 0008

MP Biomedicals is dedicated to giving scientists and researchers innovative, quality tools and superior service to aid them in their quest for ground-breaking discovery and turning the hope for life-changing solutions into a reality.The company manufactures and sells more than 55,000 products and is one of the only companies in the industry to offer a comprehensive line of life science, fine chemical and diagnostic products. MP Biomedicals is a world-wide corporation, with ISO-certified and FDA-approved manufacturing and distribution facilities throughout the globe and headquartered in Southern California. A vast network of global distributors and satellite facilities and offices throughout Europe, Asia, Australia and the Americas assures customers top quality products delivered when and where needed.No matter how dynamic the evolution of the life science and biotechnology markets, we remain committed to supporting our customers in their efforts to make new discoveries. From basic research, through scale-up, to full-scale production and diagnostic testing, MP Biomedicals serves every industry need – from specialized areas of research to supplying large scale quantities of fine chemicals. Our customers partner with us because they want a long-time player and reliable colleague in the fields of life science research and diagnostics. MP Biomedicals will never rest in our odyssey to remain at the forefront of discovery in the ever-changing biomedical industry.

PT. ROHTO LABORATORIES INDONESIA213 +62 877-8071-2023

ROHTOs first door opened in 1889 as Shintendo Yamada Anmin Pharmacy, a small family drugstore run by Yasutami Yamada in Osaka, Japan. The company was a pioneer in over-the-counter medicines and consumer healthcare products. Fifty years later, The pharmacy become ROHTO Pharmaceutical Company, Ltd. and now Rohto Pharmaceutical Company, Ltd is one of the leading company listed in Tokyo and Osaka Stock Exchange.Mentholatum was founded in 1889 in Wichitam Kansas. Starting out as small purveyot of soaps and toiletries, Mentholatum grew into an international manufacturer and marketer of non-prescription drugs with a reputation for quality and value. In 1988, ROHTO Pharmaceutical Company, Ltd. acquired The Mentholatum Compaty,Inc.Today the combined ROHTO group has established 23 companies worldwide with prodcut available to customers in more than 130 countries. The ROHTO and Mentholatum names are synonymuous with the higest standards of quality and innovation.Driven by scientific research technology, and keeping a pulse on consumers aspirations, the global Rohto Mentholatum teams continue to create better solutions through developing high quality, innovative new products. We want these to exceed our consumers expectations, to generate satisfaction and happiness to our users.Our core focus has always been and will continue to be on our customers, our associates and aour societies. Event though we have re-invented our product as many times during our history, our core philosophy has not changed. We are thankful that we have the oportunity to serve and create a better world.Rohto proclain to create a waves of Happy Surprises for our customers, continue to develop hight quality products for our health and beauty care that can give more benefit to users.In Indonesia, ROHTO that has also been known as eye drops products quality and trusted that market entry to Indonesia since 1934 and became a very -wellknown up to now.

Top Pharmaceuticals Companies in Indonesia

Key Statistics from 2022

In 2022, Indonesia's GDP is projected to reach USD 1.22 trillion, representing a growth rate of 5.1%. The pharmaceuticals industry plays a critical role in this growth, with a contribution of approximately 1.5% to the country's GDP. The industry has also created employment opportunities for thousands of Indonesians, with over 150,000 people currently employed in the pharmaceuticals sector.

Factors Contributing to Growth and Success

One of the key factors contributing to the growth and success of Indonesia's pharmaceuticals industry is the country's large and growing population. With a population of over 270 million, Indonesia is one of the world's largest markets for pharmaceuticals, providing significant opportunities for growth and investment in the sector.

Another factor contributing to the growth of the pharmaceuticals industry in Indonesia is government initiatives aimed at improving access to essential medicines and promoting domestic production. The government has launched a number of initiatives to support the development of the pharmaceuticals industry, including investment in research and development, and the establishment of drug manufacturing facilities.

Industry Growth and Comparison to Previous Years

The pharmaceuticals industry in Indonesia has experienced significant growth in recent years, with the sector's value increasing by 7.5% in 2021. This growth is expected to continue in 2022 and beyond, with the industry projected to grow at a CAGR of 8.1% between 2022 and 2027.

Compared to previous years, the pharmaceuticals industry in Indonesia has undergone a transformation, with a shift towards the use of advanced technologies such as artificial intelligence, automation, and digitalization. This has resulted in increased efficiency, reduced costs, and improved patient outcomes, making the industry more competitive and attractive to investors.

Key Trends in Indonesia's Pharmaceuticals Industry

Digital Health: One of the key trends in the pharmaceuticals industry in Indonesia is the growing adoption of digital health technologies, such as telemedicine and mobile health applications. These technologies are improving access to healthcare services and making it easier for patients to manage their health.

Personalized Medicine: Another key trend in the pharmaceuticals industry in Indonesia is the increasing focus on personalized medicine. Advances in genetic testing and targeted therapies are allowing healthcare providers to tailor treatments to individual patients, improving efficacy and reducing side effects.

Challenges

Despite the growth and success of Indonesia's pharmaceuticals industry, there are several challenges that the sector must address to sustain its growth trajectory. These challenges include:

Regulatory Environment: The pharmaceuticals industry in Indonesia is facing a complex regulatory environment, which can make it challenging for companies to bring new drugs to market. Addressing this challenge will require concerted efforts from the government to streamline regulatory processes and create a more conducive business environment.

Intellectual Property: The pharmaceuticals industry in Indonesia is also facing challenges related to intellectual property, including patent infringement and counterfeit drugs. Addressing this challenge will require improved enforcement of intellectual property laws and increased collaboration between industry stakeholders.

Future Outlook

Despite the challenges facing the industry, the outlook for Indonesia's pharmaceuticals sector remains positive. With a large and growing population, increasing demand for healthcare services, and government initiatives aimed at improving access to essential medicines, the industry is poised for continued growth in the years to come.

In addition, advances in digital health technologies and personalized medicine are opening up new opportunities for the industry, improving patient outcomes and driving innovation. However, addressing regulatory and intellectual property challenges will be critical to ensuring sustained growth and competitiveness in the long term.

Conclusion

In conclusion, the pharmaceuticals industry is a critical component of Indonesia's healthcare sector, providing essential medicines and contributing significantly to the country's GDP and employment figures. The industry's success is attributed to a number of factors, including a large and growing population, government initiatives aimed at improving access to essential medicines, and the adoption of advanced technologies.

However, the industry is also facing several challenges, including a complex regulatory environment and intellectual property issues. Addressing these challenges will require concerted efforts from the government and industry stakeholders to ensure sustained growth and competitiveness.

Looking ahead, the future outlook for Indonesia's pharmaceuticals sector remains positive, with ample opportunities for growth and investment. The industry is poised to continue contributing to the country's development and to play a critical role in shaping the future of Indonesia's healthcare sector. However, addressing regulatory and intellectual property challenges and investing in digital health and personalized medicine will be critical to ensuring the industry's sustainability and competitiveness in the long term.

undefined's picture
By Melissa Goh
Published on 13 May 2023